Citi raised the firm’s price target on Boston Scientific (BSX) to $107 from $98 and keeps a Buy rating on the shares. The firm also added the shares to Citi’s Focus List. It expects momentum of the shares to continue in 2025. Next year’s growth drivers should be a continuation of the 2024 story – continuing to expand Farapulse pulsed-field ablation and Watchman left atrial appendage closure adoption and penetration, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific price target raised to $101 from $98 at Canaccord
- Boston Scientific participates in a conference call with Truist
- Boston Scientific to acquire Intera Oncology, terms not disclosed
- Boston Scientific Launches 2025 Incentive Programs
- Boston Scientific put volume heavy and directionally bearish